Diagnostic value of Candida mannan antigen and anti-mannan IgG and IgM antibodies for Candida infection.
Adult
Aged
Aged, 80 and over
Antigens, Fungal
/ blood
Area Under Curve
Candida
/ immunology
Candidemia
/ diagnosis
Candidiasis
/ diagnosis
Case-Control Studies
Cohort Studies
Confidence Intervals
Female
Humans
Immunoglobulin G
/ blood
Immunoglobulin M
/ blood
Likelihood Functions
Male
Mannans
/ analysis
Middle Aged
Odds Ratio
Predictive Value of Tests
ROC Curve
Retrospective Studies
Sensitivity and Specificity
Candida infection
Candida mannan
anti-mannan IgG
colonisation
rapid diagnosis
Journal
Mycoses
ISSN: 1439-0507
Titre abrégé: Mycoses
Pays: Germany
ID NLM: 8805008
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
received:
30
08
2019
revised:
16
11
2019
accepted:
18
11
2019
pubmed:
23
11
2019
medline:
1
9
2020
entrez:
23
11
2019
Statut:
ppublish
Résumé
To assess the diagnostic value of serum Candida mannan antigen (MN) and anti-mannan IgG and IgM antibodies for candidiasis. This study was a prospective cohort study. Clinical data and venous blood samples from 23 medical centres in Beijing, China were collected between 1 January 2017 and 31 December 2018. All collected specimens were tested within one week for serum Candida MN and IgG and IgM antibodies using an ELISA kit. A total of 452 patients were enrolled, including 188 patients in the Candida exposure groups (56 patients with Candida bloodstream infection, 69 patients with Candida-positive tracheal aspirate cultures and 63 patients with Candida-positive urine cultures) and 264 patients in the control groups (212 healthy controls and 52 patients with bacteraemia). The receiver operating characteristic (ROC) curve of the 56 patients with Candida bloodstream infection and 212 healthy controls showed that serum MN and IgG had good diagnostic value. The area under the ROC curve (AUC) values were 0.812 (95% CI, 0.750-0.873) and 0.866 (95% CI, 0.808-0.924), respectively, wherein the MN specificity and sensitivity were 86.79% and 60.71%, and the IgG were 84.43% and 80.36%, respectively. The AUC of the combination of serum MN and IgG was 0.871(95% CI, 0.813-0.929), and the specificity and sensitivity were 93.87% and 57.14%. The serum levels of Candida MN and its IgG antibody have diagnostic value for Candida bloodstream infection, and combination of MN and IgG can improve diagnostic specificity and may provide a new approach for diagnosis of candidaemia.
Substances chimiques
Antigens, Fungal
0
Immunoglobulin G
0
Immunoglobulin M
0
Mannans
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
181-188Subventions
Organisme : Capital Health Research and Development of Special
ID : CN, 2016-1-5015
Organisme : Young Talents Lifting Project of China Association for Science and Technology
ID : 17-JCJQ-QT-036
Informations de copyright
© 2019 Blackwell Verlag GmbH.
Références
Bongomin F, Gago S, Oladele RO, Denning DW. Global and multi-national prevalence of fungal diseases-estimate precision. J Fungi. 2017;3:57.
Gunsalus KT, Tornberg-Belanger SN, Matthan NR, Lichtenstein AH, Kumamoto CA. Manipulation of host diet to reduce gastrointestinal colonization by the opportunistic pathogen Candida albicans. mSphere. 2016;1.
Le J, Tran TT, Bui I, Wang MK, Vo A, Adler-Shohet FC. Time to initiation of antifungal therapy for neonatal candidiasis. Antimicrob Agents Chemother. 2013;57:2550-2555.
Hsu DI, Nguyen M, Nguyen L, Law A, Wong-Beringer A. A multicentre study to evaluate the impact of timing of caspofungin administration on outcomes of invasive candidiasis in non-immunocompromised adult patients. J Antimicrob Chemother. 2010;65:1765-1770.
Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother. 2005;49:3640-3645.
Antinori S, Milazzo L, Sollima S, Galli M, Corbellino M. Candidemia and invasive candidiasis in adults: a narrative review. Eur J Intern Med. 2016;34:21-28.
Lefort A, Chartier L, Sendid B, et al. Diagnosis, management and outcome of Candida endocarditis. Clin Microbiol Infect. 2012;18:E99-E109.
Nguyen MH, Wissel MC, Shields RK, et al. Performance of Candida real-time polymerase chain reaction, β-D-glucan assay, and blood cultures in the diagnosis of invasive candidiasis. Clin Infect Dis. 2012;54:1240-1248.
Clancy CJ, Nguyen MH. Finding the "missing 50%" of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. Clin Infect Dis. 2013;56:1284-1292.
Morjaria S, Frame J, Franco-Garcia A, Geyer A, Kamboj M, Babady NE. Clinical performance of (1,3) beta-D-glucan for the diagnosis of Pneumocystis Pneumonia (PCP) in cancer patients tested with PCP polymerase chain reaction. Clin Infect Dis. 2019;69(8):1303-1309.
Zhang LI, Guo Z, Xie S, et al. The performance of galactomannan in combination with 1,3-β-D-glucan or aspergillus-lateral flow device for the diagnosis of invasive aspergillosis: evidences from 13 studies. Diagn Microbiol Infect Dis. 2019;93:44-53.
Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of Candidiasis: 2016 update by the infectious diseases society of America. Clin Infect Dis. 2016;62:e1-e50.
Pappas PG, Lionakis MS, Arendrup MC, Ostrosky-Zeichner L, Kullberg BJ. Invasive candidiasis. Nat Rev Dis Primers. 2018;4:18026.
Kullberg BJ, Arendrup MC. Invasive Candidiasis. N Engl J Med. 2015;373:1445-1456.
McCarty TP, Pappas PG. Invasive Candidiasis. Infect Dis Clin North Am. 2016;30:103-124.
Clancy CJ, Nguyen MH. Diagnosing invasive Candidiasis. J Clin Microbiol. 2018;56:5.
Groll AH, Castagnola E, Cesaro S, et al. Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. Lancet Oncol. 2014;15:e327-e340.
Graus MS, Wester MJ, Lowman DW, et al. Mannan molecular substructures control nanoscale glucan exposure in Candida. Cell Rep. 2018;24:2432-2442.e5.
Dominguez E, Zarnowski R, Sanchez H, et al. Conservation and divergence in the Candida species biofilm matrix Mannan-Glucan complex structure, function, and genetic control. MBio. 2018;9(2):e00451-18.
Duettmann W, Koidl C, Krause R, Lackner G, Woelfler A, Hoenigl M. Specificity of mannan antigen and anti-mannan antibody screening in patients with haematological malignancies at risk for fungal infection. Mycoses. 2016;59:374-378.
Martínez-Jiménez MC, Muñoz P, Valerio M, et al. Candida biomarkers in patients with candidaemia and bacteraemia. J Antimicrob Chemother. 2015;70:2354-2361.
Shibata N, Kobayashi H, Suzuki S. Immunochemistry of pathogenic yeast, Candida species, focusing on mannan. Proc Jpn Acad Ser B Phys Biol Sci. 2012;88:250-265.
Huppler AR, Fisher BT, Lehrnbecher T, et al.Role of molecular biomarkers in the diagnosis of invasive fungal diseases in children. J Pediatric Infect Dis Soc. 2017;6(suppl_1):S32-S44.
Mantadakis E， Pana ZD， Zaoutis T. Candidemia in children: epidemiology, prevention and management. Mycoses. 2018;61:614-622.